Effect of UGT Genetic Variation on Pharmacokinetics of Empagliflozin
Overview
- Phase
- Phase 3
- Intervention
- Empagliflozin 10 milligram
- Conditions
- Pharmacogenomic
- Sponsor
- Ain Shams University
- Enrollment
- 18
- Locations
- 1
- Primary Endpoint
- Pharmacokinetic parameters
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The aim of this works is to investigate the effect of genetic polymorphism of snps on human response to treatment with empagliflozin and its correlation with with pharmacokinetic parameters in Egyptian subjects
Detailed Description
Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, therefore resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia and also assists weight loss and blood pressure reduction. ABSORPTION Following oral administration, peak plasma concentrations were reached at 1.5 hours post-dose and then declined in a biphasic manner with a rapid distribution phase and a relatively slow terminal phase. Administration following a high-fat and high-calorie meal results in a slightly lower exposure with area under the curve (AUC) decreasing by approximately 16% and Cmax decreasing by approximately 37% compared to fasted condition. METABOLISM In vitro studies suggest that empagliflozin is primarily metabolized by glucuronidation by 5'-diphospho-glucuronosyltransferases UG2B7, UGT1A3, UGT1A8, and UGT1A9. The most abundant metabolites are three glucuronide metabolites: 2-O-, 3-O-, and 6-O-glucuronide. Empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms. It is a substrate for p-glycoprotein (p-gp), however in vitro studies suggest that it is unlikely to cause interactions with drugs that are p-gp substrates. After oral administration, empagliflozin was 41.2% eliminated in feces and 54.4% eliminated in urine. Terminal elimination half life was found to be 12.4 h based on population pharmacokinetic analysis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy adult volunteers
- •Age between (18-45 years)
- •Normal BMI.
- •Understand the procedures and are willing to participate and gave their final written consent prior to the commencement of the study procedures.
- •The volunteers will be asked to provide a complete medical history, and complete a physical examination, laboratory tests \[hematology, clinical chemistry, urinalysis, serology (including hepatitis B surface antigen, anti-hepatitis C virus and antihuman immunodeficiency virus antibody).
Exclusion Criteria
- •Treatment with any known enzyme-inducing/inhibiting agents within 30 days prior to the start of the study and throughout the study.
- •Subjects who have taken any medication less than two weeks of the trials starting date.
- •Susceptibility to allergic reactions to study drugs.
- •Any prior surgery of the gastrointestinal tract that may interfere with drug absorption.
- •Gastrointestinal diseases.
- •Renal diseases.
- •Cardiovascular diseases.
- •Pancreatic disease including diabetes.
- •Hepatic diseases.
- •Hematological disease or pulmonary disease
Arms & Interventions
Study Group
Empagliflozin
Intervention: Empagliflozin 10 milligram
Outcomes
Primary Outcomes
Pharmacokinetic parameters
Time Frame: 48 hours
AUC0→∞
Bioavailability parameters
Time Frame: 24 hours
Cmax
Secondary Outcomes
- Secondary outcome(48 hours)